ClinicalTrials.gg
TerminatedNCT03783884RESCUE 3Updated Nov 12, 2026Results posted

A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation

An interventional study of Lungpacer Diaphragm Pacing Therapy in Ventilator Induced Diaphragm Dysfunction (VIDD), sponsored by Lungpacer Medical Inc.. Terminated at 33 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Lungpacer Medical Inc. · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Low enrollment rate.
Updated Nov 12, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Ventilator-Induced Lung Injury with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Ventilator-Induced Lung Injury · United States.

Enrollment
3rd of 18
223 · median 31
Started
2019
the only one that year
No phase
14 of 23
3 open now
Registered
10th of 23
by date

Among the 23 studies in Ventilator-Induced Lung Injury with a site in United States, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2019, is one of 14 with no phase, and was the 10th registered.

Ventilator-Induced Lung Injury

122 studies on the registry are indexed under Ventilator-Induced Lung Injury; 40 are open to participants now.

Browse Ventilator-Induced Lung Injury studies →

Open to participants now

4 of the 23 studies in Ventilator-Induced Lung Injury with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Ventilator-Induced Lung Injury studies recruiting now, 15 (68%) set no upper age limit and 5 (23%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Ventilator-Induced Lung Injury with a site in United States, or all of them as a file.
02

Study summary

This clinical investigation is an open-label, multi-center, randomized clinical trial (RCT) to demonstrate the safety and effective performance of the Lungpacer DPTS (plus standard of care) as compared to Control (standard of care only) in patients aged 18 years or older who are receiving mechanical ventilation. Eligible Subjects will have received mechanical ventilation for ≥96 hours (4 days) and have failed two weaning attempts.

The goal or outcome is to show a numerically greater proportion of subjects weaned in the Treatment (Lungpacer DPTS) group as compared to the Control group.

Read the detailed description

The intended patient population is applicable for Lungpacer Diaphragm Pacing Therapy (DPT) because there are no noninvasive alternative treatments for patients who are difficult to wean from MV (i.e., ≥96 hours (4 days) on MV) or who have required prolonged MV (>7 days). The intended patient population includes approximately one-third of all patients on mechanical ventilation. Under standard of care, approximately 50% of these patients will recover from mechanical ventilation (Jung, 2016). Standard of care involves daily weaning attempts, known as Spontaneous Breathing Trials (SBTs) or Ventilator Liberation Trials (VLTs) that are intended to encourage diaphragm use and strengthening over time.Therefore, Lungpacer DPT efficacy evaluation must be compared to standard of care in a Control group. Lack of recovery from mechanical ventilation may be due to the inability of a patient to participate in VLTs or weaning attempts, due to extensive diaphragm weakness or sedation, the inability of VLTs to induce sufficient diaphragm strengthening, or co-morbidities that prevent recovery.

03

Conditions studied

  • Ventilator Induced Diaphragm Dysfunction (VIDD)

Keywords

  • VIDD
  • Diaphragm Atrophy
  • Weaning Failure
  • Ventilator Liberation Trial (VLT)
  • Spontaneous Breathing Trial (SBT)
  • Ventilator-Induced Lung Injury (VILI)
  • Phrenic Nerve Stimulation
  • Maximal Inspiratory Pressure
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are 18 years or older, and,
  2. Have been mechanically ventilated for ≥96 hours (4 days), and,
  3. Have satisfied the Readiness-to-Wean criteria, and,
  4. Have failed at least 2 weaning attempts (that were conducted at least 48 hours after initiation of MV, and, that were conducted on different calendar days, and, at least one of which was the protocol-specific Ventilator Liberation Trial).

Exclusion criteria

Exclusion Criteria:

  1. Maximal Inspiratory Pressure (MIP) (absolute value) >50 cm H2O;
  2. Invasive mechanical ventilation >90 days;
  3. Currently on extracorporeal membrane oxygenation (ECMO);
  4. Weaning failure due to hypervolemia;
  5. Medical history (including imaging) or known anatomy that prevents percutaneous insertion of the Catheter into the intended thoracic vein on the left side.
  6. Clinically overt congestive heart failure that is preventing weaning;
  7. Currently being treated with neuromuscular blockade;
  8. Pre-existing neurological, neuromuscular or muscular disorder that could affect the respiratory muscles;
  9. Pre-existing severe chronic pulmonary fibrosis;
  10. Pleural effusions occupying greater than one third of the pleural space on either side;
  11. >45 kg/m2;
  12. Known or suspected phrenic nerve paralysis;
  13. Any electrical device (implanted or external) that may be prone to interaction with, or interference from the Lungpacer DPTS including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators;
  14. Current hemodynamic instability, sepsis or septic shock;
  15. Prior bacteremia reported within the last 48 hours;
  16. Anticipating withdrawal of life support and/or shift to palliation as the goal of care;
  17. Known or suspected to be pregnant or lactating;
  18. Currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Active comparator
    Treatment

    Subject receives Lungpacer Catheter for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation.

    Device: Lungpacer Diaphragm Pacing Therapy

  • No intervention
    Control

    Subject does not receive Lungpacer Catheter or DPT. Subject receives only Standard of care for weaning from mechanical ventilation.

Interventions

  • DeviceLungpacer Diaphragm Pacing Therapy

    Transvenous phrenic nerve stimulation to induce diaphragm contraction.

    Also known as: Lungpacer DPTS, AeroPace System

06

What researchers measure

Primary outcomes

  1. Successful Weaning

    Cumulative percentage of subjects successfully weaned by Day 30.

    Time frame: Through Day 30

  2. Adverse Event Profile

    Characterize the adverse event profile to support an observed consistent risk profile for subjects randomized to Treatment compared to subjects randomized to Control. Percentage of subjects with adverse events (AE) and serious adverse events (SAE) were summarized for the Treatment group and the Control group by system organ class (SOC) and lower level term. No formal statistical hypothesis test or criterion for the primary safety endpoint was defined.

    Time frame: 30 days

Secondary outcomes

  1. Days on Mechanical Ventilation (MV)

    The average days on mechanical ventilation from Day 1 to removal from MV associated with successful weaning or Day 30, whichever comes first, will be statistically significantly smaller for subjects randomized to Treatment as compared to subjects randomized to Control.

    Time frame: Successful weaning or Day 30

  2. Maximal Inspiratory Pressure (MIP) Change

    The mean improvement in inspiratory muscle strength as shown by the change in Maximal Inspiratory Pressure (MIP) from randomization to last available measure in subjects randomized to Treatment is superior to that in subjects randomized to Control.

    Time frame: Baseline last available measure through Day 30.

  3. Rapid Shallow Breathing Index (RSBI) Change

    To determine change in Rapid Shallow Breathing Index (RSBI) from randomization to last available measure in subjects randomized to Treatment as compared to Control. RSBI measures the ratio of the respiratory rate to Tidal Volume in breaths/min/L and is commonly used as an index for weaning success. A reduction in RSBI is considered as clinical improvement.

    Time frame: Baseline to last available measure through Day 30.

  4. Survival

    Cumulative percentage of subjects who survived through Day 30.

    Time frame: 30 days

Other outcomes

  1. Re-instatements of MV (After Successful Weaning) Through Day 30.

    Assessment of re-instatements of MV in subjects who were successful weaned through Day 30 in the Treatment group as compared to the Control group.

    Time frame: Through Day 30.

  2. Tracheotomy After Randomization

    Assessment of percentage of subjects after randomization to Day 30 that required tracheostomy in the Treatment group as compared to the Control group.

    Time frame: Through 30 days

  3. ICU Discharges to Day 30.

    Assessment of ICU discharges to Day 30 in the Treatment group as compared to the Control group.

    Time frame: through 30 days

  4. Hospital Discharges to Day 30.

    Assessment of hospital admissions and discharges to Day 30 in the Treatment group as compared to the Control group.

    Time frame: through 30 days

07

Results

Posted Nov 12, 2026

Participant flow

Adaptive from N=200 to N=400 randomized subjects based on a Bayesian group sequential design.

Participant flow — Overall Study
MilestoneTreatmentControl
Started109114
Completed102114
Not completed70
Withdrew: Treatment catheter unable to be placed successfully in 7 subjects.70

Outcome measures

PrimarySuccessful Weaning

Cumulative percentage of subjects successfully weaned by Day 30.

Time frame:
Through Day 30
Reported as:
Number · Cumulative percentage of subjects
Successful Weaning
Cumulative percentage of subjectsTreatmentControl
Successful Weaning74.2 (66.5 to 80.9)63.7 (55.8 to 70.9)
Statistical analysis
  • Treatment vs Control · Bayesian Kaplan-Meier analysis · Hazard ratio (hr): 1.35Credible Interval for the HR of 1.35 was (1.009, 1.777). The posterior probability for weaning success for (HR \>1) was 97.9%.
PrimaryAdverse Event Profile

Characterize the adverse event profile to support an observed consistent risk profile for subjects randomized to Treatment compared to subjects randomized to Control. Percentage of subjects with adverse events (AE) and serious adverse events (SAE) were summarized for the Treatment group and the Control group by system organ class (SOC) and lower level term. No formal statistical hypothesis test or criterion for the primary safety endpoint was defined.

Time frame:
30 days
Reported as:
Number · Percentage of subjects
Adverse Event Profile
Percentage of subjectsTreatmentControl
Adverse Event Profile67.952.6
SecondaryDays on Mechanical Ventilation (MV)

The average days on mechanical ventilation from Day 1 to removal from MV associated with successful weaning or Day 30, whichever comes first, will be statistically significantly smaller for subjects randomized to Treatment as compared to subjects randomized to Control.

Time frame:
Successful weaning or Day 30
Reported as:
Mean · days
Days on Mechanical Ventilation (MV)
daysTreatmentControl
Days on Mechanical Ventilation (MV)14.57 ± 0.93617.03 ± 0.881
Statistical analysis
  • Treatment vs Control · Bayesian · Mean difference (final values): -2.448 · 95% CI -4.967 to 0.078The secondary endpoint of days on MV was pre-specified to meet probability of statistical success at Pr(μΤ \< μC) \> 97.5%.
SecondaryMaximal Inspiratory Pressure (MIP) Change

The mean improvement in inspiratory muscle strength as shown by the change in Maximal Inspiratory Pressure (MIP) from randomization to last available measure in subjects randomized to Treatment is superior to that in subjects randomized to Control.

Time frame:
Baseline last available measure through Day 30.
Reported as:
Mean · cm H2O
Maximal Inspiratory Pressure (MIP) Change
cm H2OTreatmentControl
Maximal Inspiratory Pressure (MIP) Change13.9 ± 19.314.9 ± 19.9
Statistical analysis
  • Treatment vs Control · t-test, 2 sided · p = 0.087
SecondaryRapid Shallow Breathing Index (RSBI) Change

To determine change in Rapid Shallow Breathing Index (RSBI) from randomization to last available measure in subjects randomized to Treatment as compared to Control. RSBI measures the ratio of the respiratory rate to Tidal Volume in breaths/min/L and is commonly used as an index for weaning success. A reduction in RSBI is considered as clinical improvement.

Time frame:
Baseline to last available measure through Day 30.
Reported as:
Mean · breaths/min/L
Rapid Shallow Breathing Index (RSBI) Change
breaths/min/LTreatmentControl
Rapid Shallow Breathing Index (RSBI) Change-35.0 ± 107.9-19.8 ± 78.2
Statistical analysis
  • Treatment vs Control · t-test, 2 sided · p = 0.2518
SecondarySurvival

Cumulative percentage of subjects who survived through Day 30.

Time frame:
30 days
Reported as:
Number · Cumulative percentage of subjects
Survival
Cumulative percentage of subjectsTreatmentControl
Survival90.9 (85.4 to 94.9)87.9 (82.3 to 92.3)
Statistical analysis
  • Treatment vs Control · Bayesian Kaplan-Meier analysis · Hazard ratio (hr): 0.785Posterior probability for improvement in survival for Treatment vs. Control of (ΗR \< 1) was 0.808 (80.8%).
Other pre-specifiedRe-instatements of MV (After Successful Weaning) Through Day 30.

Assessment of re-instatements of MV in subjects who were successful weaned through Day 30 in the Treatment group as compared to the Control group.

Time frame:
Through Day 30.
Reported as:
Number · % of subjects reinstated to MV
Re-instatements of MV (After Successful Weaning) Through Day 30.
% of subjects reinstated to MVTreatmentControl
Re-instatements of MV (After Successful Weaning) Through Day 30.5.614.5
Other pre-specifiedTracheotomy After Randomization

Assessment of percentage of subjects after randomization to Day 30 that required tracheostomy in the Treatment group as compared to the Control group.

Time frame:
Through 30 days
Reported as:
Number · percentage of subjects
Tracheotomy After Randomization
percentage of subjectsTreatmentControl
Tracheotomy After Randomization12.818.9
Other pre-specifiedICU Discharges to Day 30.

Assessment of ICU discharges to Day 30 in the Treatment group as compared to the Control group.

Time frame:
through 30 days
Reported as:
Number · percentage of subjects
ICU Discharges to Day 30.
percentage of subjectsTreatmentControl
ICU Discharges to Day 30.54.550.9
Other pre-specifiedHospital Discharges to Day 30.

Assessment of hospital admissions and discharges to Day 30 in the Treatment group as compared to the Control group.

Time frame:
through 30 days
Reported as:
Number · percentage of subjects
Hospital Discharges to Day 30.
percentage of subjectsTreatmentControl
Hospital Discharges to Day 30.38.633.0

Adverse events

Collected over AEs and SAEs were collected in RESCUE 3 from enrollment through Day 30/32 unless the subject was withdrawn from the study or died. Treatment subjects with an unsuccessful Catheter placement were followed for 48 hours after the procedure and then exited from the study. Treatment subjects who did not wean by Day 30, had their Catheter removed on Day 30 and were then followed for 48 hours (Day 32) for safety events and then exited from the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment10/109 (9.2%)39/109 (35.8%)0/109 (0%)
Control12/114 (10.5%)27/114 (23.7%)0/114 (0%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventTreatmentControl
Ventilator-associated pneumoniaInfections and infestations7/1091/114
PneumoniaInfections and infestations2/1094/114
SepsisInfections and infestations3/1090/114
PneumothoraxRespiratory, thoracic and mediastinal disorders3/1090/114
Septic shockInfections and infestations2/1093/114
Respiratory insufficiencyRespiratory, thoracic and mediastinal disorders0/1093/114
Cardiac arrestCardiac disorders2/1092/114
Cardiopulmonary arrestCardiac disorders2/1090/114
Pulseless electrical activityCardiac disorders2/1090/114
BacteremiaInfections and infestations2/1091/114

Baseline characteristics

Age, Continuous
Age, Continuous(Years)TreatmentControlTotal
Mean64.9 ± 1263.8 ± 11.564.4 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)TreatmentControlTotal
Female383876
Male7176147
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TreatmentControlTotal
Hispanic or Latino6410
Not Hispanic or Latino414485
Unknown or Not Reported6266128
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TreatmentControlTotal
American Indian or Alaska Native213
Asian336
Native Hawaiian or Other Pacific Islander000
Black or African American10717
White354277
More than one race000
Unknown or Not Reported5961120
Days on mechanical ventilation at randomization
Days on mechanical ventilation at randomization(days)TreatmentControlTotal
Mean27.9 ± 19.030.3 ± 19.529.1 ± 19.3
Maximal Inspiratory Pressure (MIP)
Maximal Inspiratory Pressure (MIP)(cm H2O)TreatmentControlTotal
Mean29.0 ± 11.228.7 ± 11.028.8 ± 11.1
08

Study locations

33 sites
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • University of Florida, Shands
    Gainesville, Florida 32610, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • U of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • Edward Hines VA Hospital
    Hines, Illinois 60141, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Indiana University Health Methodist Hospital
    Indianapolis, Indiana 46202, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Lahey Hospital and Medical Center
    Burlington, Massachusetts 01805, United States
  • Minneapolis Heart Institute Foundation
    Minneapolis, Minnesota 55407, United States
  • CHI Health Creighton University Medical Center - Bergan Mercy
    Omaha, Nebraska 68124, United States
  • Englewood Hospital Medical Center
    Englewood, New Jersey 07631, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Kent County Memorial Hospital
    Warwick, Rhode Island 02886, United States
  • Prisma Health Baptist Hospital
    Columbia, South Carolina 29203, United States
  • University of Texas Southwestern, Zale Lipshy Hospital
    Dallas, Texas 75390, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • CHU Angers
    Angers, 49933, France
  • CHU Montpellier
    Montpellier, 34295, France
  • Hôpital La Pitié-Salpêtrière
    Paris, 75651, France
  • CHU Strasbourg
    Strasbourg, 67091, France
  • Universitätsmedizin Greifswald
    Greifswald, Mecklenburg-Vorpommern 17475, Germany
  • Berlin Charite Mitte
    Berlin, 10117, Germany
  • KEM Essen
    Essen, 45276, Germany
  • SLK Löwenstein
    Löwenstein, 74245, Germany
  • Nürnberg Klinikum Nord
    Nuremberg, 90419, Germany
  • FKKG Schmallenberg
    Schmallenberg, 57392, Germany
  • Solingen Krankenhaus Bethanien
    Solingen, 42699, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Dec 2022, 42 months.

Results were first posted in Nov 2026, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2018
First posted
Dec 21, 2018
StartActual
Jun 14, 2019
Primary completionActual
Dec 28, 2022
CompletionActual
Jan 27, 2023
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Sites
1 site added, 1 site removed
Show site
  • Nürnberg Klinikum Nord · Nuremberg, Germany
Show 1 removed
  • Nürnberg Klinikum Nord · Nürnberg, Germany
Nov 12, 2026
Eligibility
2 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedMaximal Inspiratory Pressure (MIP) (absolute value) >50 cm H2O;
  • EditedCurrently on extracorporeal membrane oxygenation (ECMO);
Nov 12, 2026
Primary outcomes
1 time frame changed, 2 description edited
What changed in the outcomes
  • Time frameSuccessful Weaning30 days → Through Day 30
  • DescriptionAdverse Event Profile: how it is measured was reworded
  • DescriptionSuccessful Weaning: how it is measured was reworded
Nov 12, 2026
Documents
Secondary outcomes
6 edited, 2 time frame changed, 2 removed, 1 description edited
What changed in the outcomes
  • EditedDays on Mechanical Ventilation (MV)Time frame: Successful weaning or Day 30
  • ChangedBefore MortalityNow SurvivalTime frame: 30 days
  • Time frameMaximal Inspiratory Pressure (MIP) Change30 days → Baseline last available measure through Day 30.
  • Time frameRapid Shallow Breathing Index (RSBI) Change30 days → Baseline to last available measure through Day 30.
  • DescriptionRapid Shallow Breathing Index (RSBI) Change: how it is measured was reworded
  • Editedother outcomeCessations and reRe-instatements of MV through(After Successful Weaning) Through Day 30 or study exit.Time frame: 30 days → Through Day 30.
  • Editedother outcomeTracheotomy after randomizationAfter RandomizationTime frame: 30 days → Through 30 days
  • Editedother outcomeICU admissions and dischargesDischarges to Day 30.Time frame: 30 days → through 30 days
  • Editedother outcomeHospital admissions and dischargesDischarges to Day 30.Time frame: 30 days → through 30 days
  • Removedother outcomeTime to first successful Ventilator Liberation Trial (VLT) after randomizationTime frame: Successful VLT or 30 days
  • Removedother outcomeChange in ventilator settingsTime frame: 30 days
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Nürnberg Klinikum Nord · Nuremberg, Germany
    Show 1 removed
    • Nürnberg Klinikum Nord · Nürnberg, Germany
    Eligibility 2 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedMaximal Inspiratory Pressure (MIP) (absolute value) >50 cm H2O;
    • EditedCurrently on extracorporeal membrane oxygenation (ECMO);
    Primary outcomes 1 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameSuccessful Weaning30 days → Through Day 30
    • DescriptionAdverse Event Profile: how it is measured was reworded
    • DescriptionSuccessful Weaning: how it is measured was reworded
    Secondary outcomes 6 edited, 2 time frame changed, 2 removed, 1 description edited
    What changed in the outcomes
    • EditedDays on Mechanical Ventilation (MV)Time frame: Successful weaning or Day 30
    • ChangedBefore MortalityNow SurvivalTime frame: 30 days
    • Time frameMaximal Inspiratory Pressure (MIP) Change30 days → Baseline last available measure through Day 30.
    • Time frameRapid Shallow Breathing Index (RSBI) Change30 days → Baseline to last available measure through Day 30.
    • DescriptionRapid Shallow Breathing Index (RSBI) Change: how it is measured was reworded
    • Editedother outcomeCessations and reRe-instatements of MV through(After Successful Weaning) Through Day 30 or study exit.Time frame: 30 days → Through Day 30.
    • Editedother outcomeTracheotomy after randomizationAfter RandomizationTime frame: 30 days → Through 30 days
    • Editedother outcomeICU admissions and dischargesDischarges to Day 30.Time frame: 30 days → through 30 days
    • Editedother outcomeHospital admissions and dischargesDischarges to Day 30.Time frame: 30 days → through 30 days
    • Removedother outcomeTime to first successful Ventilator Liberation Trial (VLT) after randomizationTime frame: Successful VLT or 30 days
    • Removedother outcomeChange in ventilator settingsTime frame: 30 days
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03783884
Lead sponsor
Lungpacer Medical Inc.
Responsible party
Sponsor
First posted
Dec 21, 2018
Start date
Jun 14, 2019
Primary completion
Dec 28, 2022
Completion
Jan 27, 2023
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion